TD Cowen analyst Phil Nadeau initiates coverage on Century Therapeutics (NASDAQ: IPSC) with a Buy rating.The analyst comments "Century develops ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE